Multicentric Randomized Phase 2. Immunotherapy With CpG-ODN in Malignant Glioblastoma
Interventional
Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment
Survival
2 years
No
Alexandre CARPENTIER, MD, PhD
Principal Investigator
Hopital Lariboisiere, Päris
France: Afssaps - Agence française de sécurité sanitaire des produits de santé (Saint-Denis)
P050305
NCT00190424
September 2005
October 2010
Name | Location |
---|